EcoDrugPlus

Raf-1 Proto-Oncogene, Serine/threonine Kinase B

Ensembl ID : ENSIPUG00000011435
Gene Symbol: RAF1B
3 Cross references
152 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSIPUG00000005068
Gene Symbol: ROCK1
3 Cross references
215 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSIPUG00000002409
Gene Symbol: SRC
4 Cross references
190 Possible Orthologues:

Tek Tyrosine Kinase, Endothelial

Ensembl ID : ENSIPUG00000018505
Gene Symbol: TEK
3 Cross references
163 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSIPUG00000020297
Gene Symbol: UGCG
3 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSIPUG00000018708
Gene Symbol: WEE1
3 Cross references
205 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSIPUG00000003691
Gene Symbol: YES1
3 Cross references
206 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSIPUG00000004824
Gene Symbol: ACHE
3 Cross references
233 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSIPUG00000024714
Gene Symbol: ACVR2BA
3 Cross references
193 Possible Orthologues:

Activin Receptor Type-2b

Ensembl ID : ENSIPUG00000018290
Gene Symbol: LOC108280686
3 Cross references
195 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSIPUG00000023999
Gene Symbol: ADORA1
4 Cross references
204 Possible Orthologues:

Adenosine A1 Receptor B

Ensembl ID : ENSIPUG00000000851
Gene Symbol: ADORA1B
4 Cross references
173 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).